SCHEMBL6740976

SCHEMBL6740976

Cc1ccc(Cc2occc2C(=O)c2ccc(O)c(C3CCCC3)c2)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.38
BACE1 P56817 1/20 0.38
ADCY1 Q08828 2/20 0.36
ADCY8 P40145 1/20 0.36
THRB P10828 3/20 0.35
THRA P10827 2/20 0.35
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HSP90AA1 P07900 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
FASN P49327 2/20 0.32
TP53 P04637 1/20 0.31
KMT2A Q03164 1/20 0.31
NQO1 P15559 1/20 0.31
POLB P06746 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740349 0.71 NUDT1 (0.37) NUDT1BACE1ADCY1ADCY8THRB
SCHEMBL6731410 0.70 PTPN1 (0.37) NUDT1BACE1THRBTHRANPC1
SCHEMBL28171805 0.70 ESR1 (0.61) NUDT1BACE1THRBTHRAHSP90AA1
SCHEMBL7757797 0.67 PTGDR2 (0.36) ALDH1A1KMT2A
SCHEMBL7182409 0.66 NUDT1 (0.71) NUDT1BACE1THRBTHRARAB9A
SCHEMBL28509539 0.66 HSP90AA1 (0.50) NUDT1BACE1THRBNPC1RAB9A
SCHEMBL7818917 0.65 CYP2C19 (0.41) NPC1RAB9AALDH1A1SMN1; SMN2ESR1
SCHEMBL11054583 0.65 HSP90AA1 (0.53) NUDT1BACE1THRBNPC1RAB9A
SCHEMBL14273035 0.65 GAA (0.52) NUDT1BACE1THRBHSP90AA1ALDH1A1
SCHEMBL10428351 0.65 HSP90AA1 (0.49) NUDT1BACE1THRBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683107-B2 THERAPY OF METABOLISM DISORDERS WYETH 2004-01-27 US disclosed
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia WYETH 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073709-A1 Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, FFAR3 NUDT1 1459/4885BACE1 4301/4885ADCY1 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.